ATE288273T1 - Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen - Google Patents

Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen

Info

Publication number
ATE288273T1
ATE288273T1 AT98943457T AT98943457T ATE288273T1 AT E288273 T1 ATE288273 T1 AT E288273T1 AT 98943457 T AT98943457 T AT 98943457T AT 98943457 T AT98943457 T AT 98943457T AT E288273 T1 ATE288273 T1 AT E288273T1
Authority
AT
Austria
Prior art keywords
uridine
diphosphate
analogues
treatment
lung diseases
Prior art date
Application number
AT98943457T
Other languages
English (en)
Inventor
Richard C Boucher Jr
Sammy Ray Shaver
William Pendergast
Benjamin Yerxa
Janet L Rideout
Robert Dougherty
Dallas Croom
Original Assignee
Univ North Carolina
Inspire Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Inspire Pharmaceuticals filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE288273T1 publication Critical patent/ATE288273T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98943457T 1997-08-29 1998-08-28 Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen ATE288273T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5706497P 1997-08-29 1997-08-29
PCT/US1998/017894 WO1999009998A1 (en) 1997-08-29 1998-08-28 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases

Publications (1)

Publication Number Publication Date
ATE288273T1 true ATE288273T1 (de) 2005-02-15

Family

ID=22008285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943457T ATE288273T1 (de) 1997-08-29 1998-08-28 Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen

Country Status (14)

Country Link
US (3) US6143279A (de)
EP (1) EP1011688B1 (de)
JP (1) JP2001513568A (de)
KR (1) KR20010023359A (de)
CN (1) CN1268056A (de)
AR (1) AR013454A1 (de)
AT (1) ATE288273T1 (de)
AU (1) AU9124998A (de)
BR (1) BR9811612A (de)
CA (1) CA2300146A1 (de)
DE (1) DE69828892D1 (de)
ID (1) ID29198A (de)
WO (1) WO1999009998A1 (de)
ZA (1) ZA987847B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
WO1999005155A2 (en) 1997-07-25 1999-02-04 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
EP1011688B1 (de) * 1997-08-29 2005-02-02 The University of North Carolina at Chapel Hill Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
CA2355227A1 (en) * 1998-12-23 2000-07-06 Richard C. Boucher, Jr. Targeted gene transfer using g protein coupled receptors
DE60015734D1 (de) * 1999-02-26 2004-12-16 Inspire Pharmaceuticals Durham Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU2001272400A1 (en) * 2000-05-11 2001-11-20 Bayer Aktiengesellschaft Regulation of human p2y-like g protein-coupled receptor
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
JP2005508297A (ja) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｐ２ｙプリン受容体作用物質による関節潤滑
WO2003024980A1 (fr) * 2001-09-14 2003-03-27 Universite De Liege Preparation de composes organiques triphosphoryles eventuellement marques au phosphore 32 ou au phosphore 33
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
JP2005532254A (ja) 2001-11-06 2005-10-27 インスパイアー ファーマシューティカルズ，インコーポレイティド 炎症性疾患を治療又は予防する方法
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
WO2003072757A2 (en) * 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
JP2006505585A (ja) * 2002-10-18 2006-02-16 モリケム メディシンズ， インコーポレイテッド ランチビオティクスで眼乾燥症を処置する方法
AU2004227358B8 (en) * 2003-03-31 2009-12-10 Targeted Genetics Corporation Compounds and methods to enhance rAAV transduction
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
EP1753445A4 (de) * 2004-05-06 2009-05-20 Molichem Medicines Inc Behandlung von augenerkrankungen und augenleiden mit lantibiotischen zusammensetzungen
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
WO2008113072A2 (en) 2007-03-15 2008-09-18 Board Of Regents, The University Of Texas System Gpcr enhanced neuroprotection to treat brain injury
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2556832B1 (de) 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridin und Uridinanaloga zur Behandlung von Chronischer obstruktiver Lungenerkrankung
CA2850367C (en) 2011-09-30 2021-06-01 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
US9163055B2 (en) 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
SG10201708931XA (en) 2012-12-17 2017-12-28 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR102790402B1 (ko) * 2019-12-18 2025-04-03 주식회사 종근당 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639386A (de) * 1962-10-30
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
JPS5415073B2 (de) * 1972-09-14 1979-06-12
US4058601A (en) * 1974-07-11 1977-11-15 Chugai Seiyaku Kabushiki Kaisha Method for treating alcoholism
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (de) * 1991-06-05 1992-12-09 Synthelabo Pharmazeutische Zusammensetzungen zur Behandlung von Atemwegserkrankungen
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
CN1262556C (zh) * 1997-02-06 2006-07-05 印斯拜尔药品股份有限公司 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
EP1011688B1 (de) * 1997-08-29 2005-02-02 The University of North Carolina at Chapel Hill Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen

Also Published As

Publication number Publication date
US6022527A (en) 2000-02-08
BR9811612A (pt) 2000-08-08
US6451288B1 (en) 2002-09-17
US6143279A (en) 2000-11-07
WO1999009998A1 (en) 1999-03-04
CA2300146A1 (en) 1999-03-04
EP1011688B1 (de) 2005-02-02
ID29198A (id) 2001-08-09
AR013454A1 (es) 2000-12-27
EP1011688A1 (de) 2000-06-28
ZA987847B (en) 1999-06-28
JP2001513568A (ja) 2001-09-04
CN1268056A (zh) 2000-09-27
KR20010023359A (ko) 2001-03-26
DE69828892D1 (de) 2005-03-10
AU9124998A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
ATE288273T1 (de) Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69600307D1 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
IL131010A0 (en) Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties